Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acimtamig
- Development stage
- Phase 2
- Lead developer
- Affimed
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Acimtamig is a first-in-class tetravalent bispecific innate cell engager (ICE) designed to activate the innate immune system for the treatment of CD30-positive hematologic tumors. It is a recombinant antibody construct that binds to CD16A on natural killer (NK) cells and macrophages with two binding sites and to CD30 on tumor cells with the other two binding sites. This cross-linking brings NK cells into close proximity with tumor cells, enhancing NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) and leading to selective destruction of CD30-positive tumor cells. Acimtamig has shown promising efficacy in relapsed/refractory classical Hodgkin lymphoma and peripheral T-cell lymphoma, especially in combination with allogeneic NK cell therapies such as AlloNK. The drug was developed by Affimed Therapeutics in collaboration with The Leukemia & Lymphoma Society and University of Texas M.D. Anderson Cancer Center[1][2][3][4][5][7][8].
- Brand names
- acimtamig
- Other names
- Anti-CD30 anti-CD16A antibodyAnti-CD-30 anti-CD16A antibodyAnti-CD 30 anti-CD16A antibody
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CD30 (CD30 antigen)
Beyond the preview
Go deeper on acimtamig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acimtamig.